Pharma salesforces brought to a halt as coronavirus shutters economy

Coronavirus' spread, and the measures taken by states and cities to contain it, are forcing drugmakers like Amarin, Pfizer and Merck & Co. to pull back their sales teams from hospitals and doctors' offices.

By Ned Pagliarulo • March 17, 2020

Medicare will now cover telehealth to fight coronavirus

It's a move telemedicine companies like Teladoc and American Well have requested since well before the outbreak, but the change will only last through the national emergency designation. 

By Rebecca Pifer • March 17, 2020

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Televangelist Bakker, companies warned by FDA, FTC on fraudulent coronavirus claims

Bakker's company is among seven targeted by U.S. government for misleading consumers by promoting unproven products as treatments for COVID-19.

By Kristin Jensen • March 11, 2020

Pfizer, Amgen, Lilly spent most to lobby Congress, study finds

Spending by the industry ramped up at key times, including around the 2016 presidential election and just before the passage of the Affordable Care Act.

By Kristin Jensen • March 4, 2020

Patient group pushes Trump-backed drug pricing bill

A new national TV ad campaign from Patients For Affordable Drugs urges Congress to pass a bipartisan bill from the Senate Finance Committee. 

By Kristin Jensen • Feb. 26, 2020

Esperion adds more competition to cholesterol drug market

Following an FDA approval Friday, Esperion intends to sell bempedoic acid under the brand name Nexletol for a price of about $10 per day.

By Jacob Bell • Feb. 21, 2020

Bluebird's gene therapy hits another delay, this time in the US

The disclosure of a longer timeline until the biotech fully submits LentiGlobin for U.S. approval sent shares sliding and spurred one analyst to downgrade the stock.

By Jacob Bell • Feb. 19, 2020

Biotech executives, having pledged fair pricing, criticize drugmaker for steep hike

Belcher Pharmaceuticals priced its new injectable drug at nearly $10,000, spurring pushback from a group of leading biotech executives behind a recently published "industry commitment."

By Ned Pagliarulo • Feb. 19, 2020

Akebia locks down control over partner's new regulatory fast pass

For $10 million, Akebia gained access to Vifor Pharma's newly acquired Priority Review Voucher, which could narrow the gap between its drug and a closer-to-market rival from AstraZeneca and Fibrogen.

By Jacob Bell • Feb. 18, 2020

Coronavirus weighs on AstraZeneca's China expansion

The British drugmaker cautioned the disease outbreak could impact its sales in the country, where restrictions on travel and commerce have been imposed to contain the virus' spread.

By Jonathan Gardner • Feb. 14, 2020

Gilead launches ad campaign for key HIV drug

The drugmaker is working to expand PrEP use of Descovy as its older option Truvada loses patent protection later this year. 

By Kristen Jensen • Feb. 12, 2020

Are Novartis and Regeneron seeing the same thing?

Both companies are touting the success of their competing eye drugs. But as the market crowds, it's likely they'll bump into problems.

By Jacob Bell • Feb. 7, 2020

AbbVie's plan to replace Humira is ahead of schedule

Sales of Skyrizi and Rinvoq, AbbVie's two new immunology drugs, jumped higher in the fourth quarter, leading the pharma to raise its 2020 forecasts for them by more than two-thirds. 

By Ned Pagliarulo • Feb. 7, 2020

Biogen boosted as Mylan patent challenge fails

A patent court determined all 20 claims in a key Tecfidera patent are patentable, providing some near-term relief to Biogen and its top-seller. 

By Jacob Bell • Feb. 5, 2020

FDA approves Aimmune drug as first treatment for peanut allergy

Aimmune's next challenge will be securing insurance coverage as people allergic to peanuts still have to avoid exposure to the food.

By Jonathan Gardner • Jan. 31, 2020

Amgen, Pfizer biosimilar sales pressure top drugs

Competition is heating up for copycats to Roche's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting.

By Jonathan Gardner • Jan. 31, 2020

Novartis gives up on Advair generic, leaving Mylan as sole competitor

Development delays and an uncertain path forward led Novartis to discontinue further work on its knockoff version of the GlaxoSmithKline lung drug.

By Ned Pagliarulo • Jan. 29, 2020

Pfizer hits its biosimilar stride

The big pharma, which has criticized other companies for stifling the U.S. biosimilars market, is now poised to launch three of these copycat biologics in as many months.

By Jacob Bell • Jan. 27, 2020

Google's call for change and what it means for advertisers

Last week, Google Chrome announced a vision for a future without third-party cookies. How will upcoming changes impact health marketers?

Jan. 23, 2020

Alternate sites of care: The changing face of healthcare delivery

As the care setting evolves and diversifies, stakeholders throughout the healthcare ecosystem have to evolve in kind.

By Parijat Sharma & Matt Ruple • Jan. 21, 2020

Orchard isn't for the picking, Biohaven's Allergan headache, and who's on Vascepa?

Amarin CEO John Thero had one question for investors eager to hear about his company's plans for its heart pill, while Orchard made a case for independence.

By Jacob Bell • Jan. 16, 2020

Lilly expands half-price insulin offerings

Like rivals Novo and Sanofi, Lilly has introduced lower cost insulin alternatives to head off criticism of list price increases it's taken on its branded versions.

By Ned Pagliarulo • Jan. 15, 2020

Nektar quickly drops opioid drug after FDA panel rejection

After a decade of research, the biotech said it will withdraw its application for oxycodegol and make no further investment in the drug.

By Kristin Jensen • Jan. 15, 2020

Amag CEO to step down as troubled pharma looks to sell 2 drugs

Emerging from an activist investor fight, Amag announced a restructuring plan and 2020 sales estimates that fell short of Wall Street expectations.

By Andrew Dunn • Jan. 9, 2020

GSK's plan to take over the HIV drug market hasn't worked out

An FDA rejection and modest sales for two marketed products are challenging GSK's argument that two-drug treatments are a better way to treat HIV.

By Jacob Bell • Jan. 6, 2020